Genetic variants can drastically change how certain enzymes work. While some people are fast metabolisers — they break down drugs too quickly before the medicine even has time to act — some others are slow metabolisers: their bodies process drugs too slowly, allowing the drugs to build up to toxic levels
Read More
The indentification of two critical markers — DUOX2 and THRA — will help in better predicting which patients might face aggressive thyroid cancer disease or recurrence. For papillary thyroid cancer, this might mean developing targeted therapies for the novel subtype (iBR) or using DUOX2 for early detection. For anaplastic thyroid cancer, targeting THRA-driven plasticity could lead to breakthroughs for a cancer with few options
Read More